Can We Better Protect Hospitalized Patients With Obesity From Venous Thromboembolism? – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Walter Agenoet et al, adding:
”Can we better protect hospitalized patients with obesity from venous thromboembolism?
Patients with obesity hospitalized for acute medical illness face a substantial risk of venous thromboembolism (VTE), yet optimal thromboprophylaxis strategies remain uncertain.
In this large real-world analysis of 58,186 hospitalized adults receiving enoxaparin, researchers evaluated treatment patterns, clinical outcomes, and predictors of VTE and major bleeding (MB).
More than half of patients (56.9 percent) received high-dose enoxaparin (more than 40 mg/day), but prophylaxis was typically shorter than hospitalization (median 3 days compared with 4 days), and only 1.3 percent received post-discharge enoxaparin.
Despite prophylaxis, the cumulative 90-day incidence reached 3.2 percent for venous thromboembolism compared with 1.8 percent for major bleeding, suggesting that thrombotic risk outweighed bleeding risk in this population.
The highest venous thromboembolism risk occurred in patients hospitalized with cancer (7.8 percent), while a history of venous thromboembolism emerged as the strongest predictor of recurrent thrombosis (hazard ratio 4.1). A history of major bleeding was the strongest predictor of future major bleeding (hazard ratio 2.8). These findings support more individualized risk assessment, particularly for patients with cancer, severe obesity, or prior venous thromboembolism.
As obesity continues to rise worldwide, optimizing the dose, duration, and personalization of thromboprophylaxis remains an important clinical challenge.
Title: Venous thromboembolic and bleeding risk in population with obesity hospitalized for an acute medical illness receiving enoxaparin for thromboprophylaxis
Authors: Walter Ageno, Juan I. Arcelus, Christine Stroh, Yasmina Djoudi, Mohamed Abdel-Moneim, Irfan Khan, Ekaterina Ponomareva, Marc Carrier
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 19, 2026, 10:21Upcoming Podcast on Thalassaemia with The Lancet Haematology
-
Sep 19, 2026, 10:20Steve Helm: Cardiology and Anticoagulation Pharmacist Role Opens Near NYC
-
Sep 19, 2026, 10:12Omid Seidizadeh: A Great Pleasure to Speak on vWD at the 59th NordCoag Congress
-
Sep 19, 2026, 10:08Carsten Hansen: What Happens During a Sickle Cell Crisis?
-
Sep 19, 2026, 10:05Alan Nurden: Thyroid Hormones as Regulators of Acute Platelet Release
-
Sep 19, 2026, 10:02Oliver Weingärtner: What Can Real-World Data Teach Us about Long-Term Treatment Persistence in CP?
-
Sep 19, 2026, 09:55Ammar Alsughayir: When Transfusion Safety Becomes a Lifelong Commitment
-
Sep 19, 2026, 09:53Dilini Christina Ranasinghe: Exploring Red Cell Exchange in Sickle Cell Disease
-
Sep 19, 2026, 09:48Kanchal Mahesh: A First Step Into the World of Research